The potential translational value of the inhibition of glutamine metabolism to reduce or suppress the maintenance of stem cell potential was tested successfully by co-treating CML cells with glutaminase inhibitors together with TKi. The gene discussed is GLS; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.